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Abstract
Vincristine is an anticancer drug used to treat different types of cancer. However, vincristine has been reported to become resistant against some
cancer such as small cell lung cancer cell lines due to decreased uptake, increased drug efflux etc. To increase the uptake, vincristine loaded folic
acid–chitosan conjugated nanoparticles were synthesized using ionic gelation method at pH 2.5. 1H-NMR confirmed conjugation of folic acid with
chitosan. Blank folic acid–chitosan conjugated nanoparticles had an average size of 897.5 ± 0.90 nm, a polydispersity index of 0.738 ± 0.30 and zeta
potential of +11.2 ± 0.43 mV and found to increase in vincristine loaded folic acid−chitosan nanoparticles at different formulations due to loading of
vincristine in folic acid–chitosan conjugated nanoparticles. Fourier Transform Infrared Spectroscopy (FTIR) revealed different functional groups and
loading of vincristine in chitosan nanoparticles. X-ray diffraction (XRD) was performed to confirm the crystalline nature of the drug after loading and
face centered cubic (FCC) structure of nanoparticles. In vitro drug release study showed slow and sustained release of vincristine in phosphate buffered
saline at pH 6.7. Scanning Electron Microscopy (SEM) revealed spherical and rough surface of nanoparticles. Transmission Electron Microscopy
(TEM) confirmed loading of vincristine and size range of nanoparticles from 4.24 to 300 nm. Spectrophotometric analysis depicted maximum
encapsulation efficiency and loading capacity of 81.25% and 10.31%, respectively. Since cancer cells express folate receptors on their surface, these
vincristine loaded folic acid–chitosan conjugated nanoparticles could be used for targeted delivery against resistant cancer with some modifications.
© 2016 Tomsk Polytechnic University. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
A variety of natural molecules either alone or in combination
with radiation therapy have shown their anti-cancerous effects
[1]. Of these, vincristine is one of the vinca alkaloids which
acts as antineoplastic agent and is used to treat different types
of cancers such as breast cancer, Hodgkin’s disease, Kaposi’s
sarcoma, testicular cancer etc [2]. Vincristine binds to tubulin
and prevents its polymerization leading to blocking of mitosis
[3,4]. However, researchers reported resistance of vincristine
uptake by some cancer cell lines such as human lung-cancer
PC-9 sub line [5], human gastric carcinoma cell line SGC7901
[6], human cancer KB cell VJ-300 [7] etc.
In recent years, nanomedicine has emerged as a ray of hope
to overcome such type of resistances. Attempts have been
made by researchers to increase solubility and bioavailability
of vincristine by encapsulating in biodegradable polymeric
nanoparticles [8,9]. Among various polymers, chitosan has
attracted attention of researchers due to its unique property as
drug carrier. Chitosan is a natural polysaccharide, obtained
from chitin of arthropods like shrimp and crab [10]. Chitosan
is the deacetylated form of chitin (2-amino-2-deoxy-(1–4)-D-
glucopyranan) and exhibits excellent properties such as
biodegradability, biocompatibility and antimicrobial activity [11].
Chitosan nanoparticles are widely used to deliver hydrophobic
drugs, vitamins, proteins, nutrients and phenolics into the
biological systems and are stable and less toxic [12,13]. It
requires simple methods for preparation of anticancer drug
loaded chitosan nanoparticles thereby improving its versatility
as drug delivery agent [14]. When chitosan comes in contact
with polyanions such as sodium tripolyphosphate, it forms
inter and intramolecular cross-linkages through ionic
gelation for encapsulation of drugs [15]. Various ligands such
as folic acid can be attached to chitosan by different
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methods so that these chitosan nanoparticles become target
specific.
In the present investigation, vincristine loaded folic
acid–chitosan conjugated nanoparticles were synthesized in
different ratios. Physicochemical properties such as average
particle size, polydispersity index, zeta potential, FTIR, XRD,
SEM, TEM etc. were measured for blank and vincristine loaded
nanoparticles.
2. Materials and methods
2.1. Chemicals
Low molecular weight chitosan (≥75% deacetylation
degree), N,N′-Dicyclohexylcarbodiimide (DCC), Dimethyl
sulphoxide (DMSO), N-Hydroxysuccinimide, Pure (NHS),
Phosphate buffered saline (Dulbecco A), Folic acid, Acetate
buffer (pH 5.6), Triethylamine and Dialysis Tubing (LA653)
were purchased from HiMedia Laboratories, India. Sodium
tripolyphosphate (85%) was purchased from Sigma Aldrich. All
other chemicals and reagents used in the study were of labora-
tory grades.
2.2. Synthesis of N-Hydroxysuccinimide ester of folic acid
N-Hydroxysuccinimide ester of folic acid was synthesized
according to previously reported method with slight modifications
[16]. Briefly, 1.5 g folic acid was dissolved in 25 ml dimethyl
sulfoxide and added 2 ml N-Hydroxysuccinimide (1.0 M) and
N,N′-dicyclohexylcarbodiimide (1.0 M) each followed by addition
of 2.0 ml triethylamine. The reaction was allowed to proceed
for 17 h under stirring in the dark in a shaker. The dark pale
yellow colored by-product dicyclohexylurea was removed by
filtration using filter paper (11 μm). Filtered NHS ester of folic
acid was washed with 30% acetone and used for further research.
2.3. Synthesis of folic acid–chitosan conjugate
Folic acid was conjugated with chitosan by using the method
of Ji et al. [17] with some modifications. Briefly, 45 mg
chitosan was dissolved in 15 ml acetate buffer (pH 5.6). 1 g
N-Hydroxysuccinimide ester of folic acid was separately dis-
solved in 15 ml Dimethyl Sulphoxide and added to chitosan
solution drop wise. Mixture was stirred at 30 °C in the dark for
20 h on a laboratory shaker resulting in the formation of
folic acid–chitosan conjugate. The solution was filtered using
filter paper (11 μm) and conjugates were transferred to 2.0 ml
microcentrifuge vial and stored in refrigerator for further use.
The 1H-NMR spectra of chitosan and folic acid–chitosan con-
jugate were recorded on a 400 MHz FT NMR spectrometer
(Avance II, Bruker) using D2O as a solvent.
2.4. Synthesis of blank and vincristine loaded chitosan
nanoparticles
Blank and vincristine loaded folic acid–chitosan conjugated
nanoparticles were synthesized by ionic cross-linking with
sodium tripolyphosphate (TPP) using a previously reported
method [18] with minor modifications. Folic acid–chitosan
conjugate solution (0.2%, w/v, pH 2.5) was prepared using
acetic acid (2%, v/v) at room temperature. Sodium tripolyphos-
phate (0.5%, w/v) solution was prepared using distilled water.
For the preparation of blank nanoparticles, 100 ml folic acid–
chitosan conjugate solution was taken in a flask and 20 ml
sodium tripolyphosphate (1:5 ratios) solution was added to it
drop wise till the formation of nanoparticles suspension and
stirred for 30 minutes on a magnetic stirrer at room tempera-
ture. For the synthesis of vincristine loaded nanoparticles,
aqueous solution of vincristine (1 mg/10 ml, pH 4.77) was pre-
pared separately. Keeping folic acid–chitosan conjugate (25 ml)
and sodium tripolyphosphate (5 ml) volume constant varying
volumes of vincristine (100 μl, 200 μl, 300 μl, 400 μl) were
used for the synthesis of different ratios of nanoparticles, i.e.,
1:25, 2:25, 3:25 and 4:25, respectively and allowing the solu-
tion to stir for 30 minutes on a magnetic stirrer at room tem-
perature. Nanoparticles suspension for blank and vincristine
loaded folic acid–chitosan conjugated nanoparticles was cen-
trifuged at 16,000 rpm for 30 minutes for separating the
nanoparticles from the solution for further characterization.
2.5. Encapsulation efficiency and actual drug loading
For determination of the encapsulation efficiency (%) and
actual drug loading (%), vincristine loaded folic acid–chitosan
conjugated nanoparticles were centrifuged at 16,000 rpm for
30 min. The content of free vincristine in the supernatant was
determined by UV spectrophotometer at 220 nm using super-
natant of their corresponding blank nanoparticles without
loaded drugs as basic correction. Encapsulation efficiency and
drug loading were calculated by the following equations:
Encapsulation efficiency Drug Drug Drugtot free tot%( ) ( ) ( ) ( )= −
× 100
Actual drug loading w w
Mass of vincristine in chitosan n
%( )
= anoparticles
Mass of chitosan nanoparticles recovered ×100.
2.6. Storage stability of nanoparticles
Fresh vincristine loaded folic acid–chitosan conjugated
nanodispersion (200 μl) was separately added to 50 ml of phos-
phate buffer saline solutions with different pH (5, 6, 6.7, 7.2 and
7.7). Samples in all ratios (1:25, 2:25, 3:25, 4:25) were also
stored in deionized water to calculate relative light transmit-
tance (Ti/T %). The samples were stored at room temperature.
The light transmittance was measured at 220 nm by UV spec-
trophotometer at scheduled time intervals [19]. Relative light
transmittance was calculated as per the following equation:
Ti T Transmittance of vincristine loaded folic acid
chitos
% =
− an conjugated nanoparticles at each pH
Transmittance at deionized water ×100
2.7. Characterization of blank and vincristine loaded folic
acid–chitosan nanoparticles
Blank and vincristine loaded folic acid–chitosan conjugated
nanoparticles were characterized using different techniques.
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2.7.1. Average size, polydispersity index and zeta potential
Average size, polydispersity index and zeta potential of
blank and vincristine loaded folic acid–chitosan conjugated
nanoparticles were determined by dynamic laser scattering
(DLS) technique using Malvern Zetasizer Nanoseries Nanos
ZS90 (Malvern Instruments, UK). Before measurement, the
nanoparticles (50 μl) were dispersed in water (950 μl) to make
a total volume of 1 ml and readings were obtained at 25 °C.
2.7.2. Fourier transformation infrared spectroscopy (FTIR)
The Fourier transform infrared (FTIR) spectra of blank
nanoparticles, vincristine and vincristine loaded chitosan
nanoparticles of different ratios (1:25, 2:25, 3:25 and 4:25)
were analyzed by Perkin Elmer-Spectrum RX-IFTIR. Scanning
range was selected from 4000 cm−1 to 400 cm−1 and resolution
was 1 cm−1.
2.7.3. X-ray diffraction (XRD)
X-ray diffraction (XRD) of vincristine loaded folic acid–
chitosan nanoparticles of different ratios (1:25, 2:25, 3:25 and
4:25) was analyzed by Panalytical’s X’Pert Pro, Netherlands
with Cu K-alpha-1 as radiation and nickel metal as beta filter in
θ–2θ configuration.
2.7.4. In vitro release study
The in vitro release profile of vincristine from folic acid–
chitosan conjugated nanoparticles was determined by dialysis
tubing (molecular weight cut off 12,000–14,000) at 37 °C.
10 mg of nanoparticles was added to 1 ml phosphate buffered
saline (pH 6.7) and poured in a dialysis membrane, dipped in
phosphate buffered saline (pH 6.7) in different beakers. The
beakers were placed on a laboratory shaker. After definite inter-
vals of time, 1 ml of phosphate buffered saline (pH 6.7) was
taken out and same amount of buffer was added. The absor-
bance of resulting solution was measured at 220 nm to deter-
mine the concentration of vincristine in the buffer.
2.7.5. Scanning electron microscopy (SEM)
The morphology of blank and vincristine loaded chitosan
nanoparticles was examined by Scanning Electron Microscopy
(JEOL Model JSM – 6390LV). Few milliliters of samples were
placed in aluminum stubs and then coated with platinum. The
SEM images were taken with an acceleration voltage of 15 kV.
2.7.6. Transmission electron microscopy (TEM)
Size of blank and vincristine loaded FA–CS nanoparticles
was examined by Transmission Electron Microscopy (Jeol/JEM
2100) with an operating voltage of 200 kV. Loading of vincris-
tine in chitosan nanoparticles was also confirmed by TEM.
3. Results and discussion
3.1. Synthesis of N-Hydroxysuccinimide ester of folic acid
and folic acid–chitosan conjugate
N-Hydroxysuccinimide is an activating agent of carboxylic
acid which activated carboxylic group of folic acid during 17 h
stirring in the dark. N-Hydroxysuccinimide reacted with folic
acid in the presence of N,N′-dicyclohexylcarbodiimide to produce
yellow colored dicyclohexylurea confirming the synthesis of
Fig. 1. 1H NMR spectrum of (a) chitosan and (b) folic acid–chitosan conjugate
showing binding of folic acid with chitosan.
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N-Hydroxysuccinimide ester of folic acid. Further, folic acid
was conjugated to chitosan following the N-Hydroxysuccinimide
ester of folic acid reaction to get folic acid–chitosan conjugate.
1H NMR proved conjugation of folic acid to chitosan. Two
carboxylic groups (-COOH) are present at the end position of
folic acid and it has been supported by literature that γ-COOH
is more reactive [20]. Folic acid–chitosan conjugate was
synthesized by the formation of amide bond between activated
N-Hydroxysuccinimide ester of folic acid and the primary amine
groups of chitosan. The structure of chitosan and folic
acid–chitosan conjugate by 1H-NMR spectroscopy is shown in
Fig. 1 and b. The peaks at 2.6484 ppm were due to acetamino
group CH3 and CH peak appeared at 3.4269–3.5358 ppm due
to carbons 3, 4, 5, and 6 of glucosamine ring of chitosan (Fig.
1a). Appearance of the peculiar signals at 2.5680 ppm was due
to the formation of amide bond through reaction between activated
folic acid ester and the primary amine groups of chitosan as
shown in Fig. 1b and corresponds to the folic acid proton from
the H22 [21]. 1H-NMR spectroscopic data were analyzed using
online software [22]. Similar results were obtained by Ji et al.
[17] while grafting folic acid to chitosan for target specific
delivery of methotrexate.
3.2. Blank and vincristine loaded chitosan nanoparticles
The folic acid–chitosan conjugated nanoparticles synthesis
occurred due to ionic interaction between positively charged
free protonated amino group (–NH3+) of the folic acid–chitosan
Fig. 2. Relative light transmittance (Ti/T) of vincristine loaded nanoparticles: (a) pH 5, (b) pH 6, (c) pH 6.7, (d) pH 7.2, (e) pH 7.6.
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conjugate and negatively charged sodium tripolyphosphate
[17]. However, size distribution of nanoparticles depends upon
the ratio of chitosan and sodium tripolyphosphate which affects
biological properties and their role [23]. Different ratios of
vincristine loaded folic acid–chitosan nanoparticles were syn-
thesized. 5-Fluorouracil loaded chitosan nanoparticles by ionic
gelation method have been reported [24]. Earlier, ferulic acid
has been loaded in chitosan nanoparticles by ionic gelation to
check anticancer activity against ME-180 human cervical
cancer cell lines [25].
3.3. Encapsulation efficiency and drug loading
Vincristine was loaded in chitosan nanoparticles due to ionic
reaction. As shown in Table 1, encapsulation efficiency (%) for
1:25, 2:25, 3:25 and 4:25 was 20 ± 0.58, 65 ± 0.53, 66.6 ± 0.23
and 81.25 ± 0.43, respectively. Maximum encapsulation was
reported in 4:25 ratio (81.25 ± 0.43%) because concentration
of vincristine was higher as compared to other ratios. However,
after crossing maximum loading capacity, more drugs could be
wasted during the synthesis process [26]. Drug loading capacity
(%) was 0.6 ± 0.15, 3.83 ± 0.19, 6.06 ± 0.97 and 10.31 ± 0.76
for 1:25, 2:25, 3:25 and 4:25 ratios, respectively. Drug loading
was found to be maximum (10.31%) for 4:25 ratio (Table 1).
Previous studies [25] have shown that ferulic acid loaded chitosan
nanoparticles with varying concentrations (1, 5, 10, 20, 40, 80,
40 μM) of ferulic acid, chitosan and sodium tripolyphosphate
have been synthesized. Maximum encapsulation efficiency of
ferulic acid (63.0 ± 2.20%) was achieved at 40 μM. Similarly,
maximum loading capacity (32.9 ± 2.1%) was found at 80 μM
concentration of ferulic acid [25]. Mitoxantrone, an anticancer
drug, has been loaded in folic acid–chitosan conjugated
nanoparticles in different ratios, i.e. 1:1, 1:2, 1:3 and 1:4 with
respect to mitoxantrone and folic acid–chitosan conjugate. It
was reported that when mitoxantrone vs folic acid–chitosan
conjugate ratio was increased from 1:4 to 1:1, the loading
capacity was also enhanced from 12.2% to 32.3%, but the
highest encapsulation efficiency (77.5%) was observed when
ratio of mitoxantrone vs folic acid–chitosan conjugate was 1:3
[27].
Table 1
Encapsulation efficiency (%) and vincristine loading (%) of chitosan
nanoparticles.
Sr. No. Ratios Encapsulation
efficiency (%)
Loading of vincristine in chitosan
nanoparticles (% w/w)
1. 1:25 20 ± 0.58 0.6 ± 0.15
2. 2:25 65 ± 0.53 3.83 ± 0.19
3. 3:25 66.6 ± 0.23 6.06 ± 0.97
4. 4:25 81.25 ± 0.43 10.31 ± 0.76
Fig. 3. Blank folic acid–chitosan conjugated nanoparticles. (a) Average particle size and polydispersity index (b) zeta potential.
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3.4. Storage stability of nanoparticles
Fig. 2 shows stability of nanoparticles at different pH up to
14 days as monitored by relative light transmittance, i.e.,
Ti/T %. There was no significant change in the turbidity of
nanoparticles stored at different pH indicating highly stable
nature of nanoparticles. An overview of Fig. 2a indicates that
there was a change in Ti/T % for 1:25, 2:25, 3:25, and 4:25 with
passage of time for pH 5. It reveals that nanoparticles were not
stable at pH 5. On the other hand at pH 6, 2:25, 3:25 and 4:25
ratios showed decrease in Ti/T % as compared to 1:25 (Fig. 2b).
This confirmed the stability of nanoparticles at 1:25 ratio at pH
6. Further, as shown in Fig. 2c (pH 6.7), only 4:25 ratio showed
decrease in relative transmittance whereas 1:25, 2:25 and 3:25
showed minor change confirming nanoparticle stability at pH
6.7. At pH 7.2, all ratios showed minor change in the relative
absorbance with passage of time except for 1:25 (Fig. 2d) which
indicates stability, whereas all ratios of nanoparticles at pH 7.6
showed constant relative absorbance with passage of time indi-
cating their high stability (Fig. 2e). So it is envisaged that the
synthesized nanoparticles were highly stable at pH 7.2 and 7.6
as compared to pH 5, 6 and 6.7. Similar results were also
obtained while monitoring stability of methotrexate in folic
acid–chitosan conjugated nanoparticles [17].
3.5. Characterization of blank and vincristine loaded
chitosan nanoparticles
3.5.1. Average size, polydispersity index and zeta potential
As shown in Fig. 3a, average size of blank chitosan
nanoparticles was 897.5 ± 0.90 nm with major percentage of
nanoparticles corresponding to the peak over 100 nm and
polydispersity index was 0.738 ± 0.30. Zeta potential of folic
acid–chitosan conjugated nanoparticles was +11.2 ± 0.43 mV
(Fig. 3b). Average size of vincristine loaded folic acid–chitosan
nanoparticles in the ratio of 1:25 was 1598.13 ± 0.60 nm with
67% peaks of 700.5 nm size, polydispersity index of 0.937 ± 0.11
and zeta potential of +9.84 ± 0.51 mV (Fig. 4a and b). Similarly,
vincristine loaded folic acid–chitosan nanoparticles at a ratio
of 2:25 showed average size of 2200 ± 0.64 nm having
nanoparticles of different percentages with polydispersity index
of 0.454 ± 0.26 and zeta potential of +7.99 ± 0.92 mV as shown
in Fig. 5a and b. Fig. 6a and b indicates vincristine loaded
folic acid–chitosan nanoparticles at a ratio of 3:25 had an
Fig. 4. Vincristine loaded folic acid–chitosan conjugated nanoparticles at a ratio of 1:25. (a) Average particle size and polydispersity index (b) zeta potential.
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average size of 2532.33 ± 0.35 nm with 69.8% of 761.3 nm
size, polydispersity index of 0.942 ± 0.01 and zeta potential of
+10.5 ± 0.46 mV, whereas vincristine loaded folic acid–chitosan
nanoparticles at a ratio of 4:25 had an average size of
3812 ± 0.38 nm with 63.2% of 1190 nm size and polydispersity
index of 0.703 ± 0.10. Zeta potential was +12.6 ± 0.2 mV (Fig. 7a
and b). This positive zeta potential is useful to cross negatively
charged cancer cell membrane. In an earlier study [17] different
sized, methotrexate loaded folic acid–chitosan conjugated
nanoparticles were synthesized at different pH. At pH 4.0 size,
polydispersity index, zeta potential was 316.9 ± 16.9 nm,
0.229 ± 0.034, 31.48 ± 2.32; at pH 4.5, 329.2 ± 13.3 nm,
0.295 ± 0.049, 29.04 ± 2.29; at pH 5.0, 358.2 ± 15.6 nm,
0.224 ± 0.040, 23.81 ± 1.85; at pH 5.5, 394.1 ± 23.0 nm,
0.256 ± 0.032, 22.84 ± 1.79 respectively.
3.5.2. Fourier transformation infrared spectroscopy (FTIR)
FTIR spectra of blank, vincristine and vincristine loaded
folic acid–chitosan conjugated nanoparticles in different ratios
are shown in Fig. 8a–f. The blank folic acid–chitosan conjugated
nanoparticles spectrum (Fig. 8a) showed a characteristic peak
at 3399.0 cm−1 (N–H stretching vibration), which was shifted
to 3391.16 cm−1, 3368.11 cm−1, 3399.0 cm−1 and 3396.0 cm−1
(N–H stretching vibration) in 1:25, 2:25, 3:25 and 4:25 ratios,
respectively. Wider peak at 3399 cm−1 demonstrated that inter-
and intra-molecular actions were enhanced in folic acid–chitosan
nanoparticles because of the tripolyphosphoric groups of sodium
tripolyphosphate linked with ammonium group of folic
acid–chitosan conjugate [28]. Peak at 1643.6 cm−1 for blank
nanoparticles was due to NH2 deformation vibration, which
indicated the linkage between sodium tripolyphosphate and
ammonium ion of the folic acid–chitosan conjugation and it
was shifted to 1627.24 cm−1, 1628.18 cm−1, 1639.5 cm−1 and
1643.3 cm−1 (NH2 deformation) for 1:25, 2:25, 3:25 and 4:25
ratios, respectively. Such shifting indicated interaction of
vincristine with folic acid–chitosan conjugated nanoparticles.
FTIR spectrum of vincristine (Fig. 8b) showed peak at
3410.43 cm−1 due to broad O–H stretching vibration. Peaks at
3055.58 cm−1 (–C–H stretching vibration), 2954.56 cm−1 (–CH3
symmetrical stretching vibration), 2675.62 cm−1 (C–H stretching
Fig. 5. Vincristine loaded folic acid–chitosan conjugated nanoparticles at a ratio of 2:25. (a) Average particle size and polydispersity index (b) zeta potential.
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vibration) and 1747.48 cm−1 (–C — O stretching vibrations)
were also observed. Similar peaks were also observed for
vincristine loaded folic acid–chitosan conjugated nanoparticles
at 2928.30 cm−1 (CH3 symmetrical stretching vibration) and
2849.32 cm−1 (C–H stretching vibration) for 1:25, 2930.24 cm−1
(CH3 symmetrical stretching vibration) and 2850.27 cm−1 (C–H
stretching vibration) for 2:25, 2954.11 cm−1, 2932.11 cm−1 (CH3
symmetrical stretching vibration) and 2850.15 cm−1 (C–H
stretching vibration) for 3:25 and 2851.13 cm−1 (C–H stretching
vibration) for 4:25, which confirmed vincristine has been loaded
in the nanoparticles. Jeevitha and Kanchana [29] also observed
shifts in peaks while loading anticancer drug Piceatannol in
Chitosan–poly(lactic acid) nanoparticles. These shifts in peaks
confirmed the loading of vincristine successfully in folic
acid–chitosan conjugated nanoparticles.
3.5.3. X-ray diffraction (XRD)
X-ray diffraction pattern of vincristine loaded folic
acid–chitosan conjugated nanoparticles in different ratios is
presented in Fig. 9. One strong peak at 2θ values (8.0674°)
was observed for 1:25 ratio which was shifted to 8.0392°,
7.6540°, and 8.0339° for 2:25, 3:25 and 4:25 ratios, respectively.
There was also a shift in small peaks (2θ values) from 15.6263°,
17.6045°, 20.5200°, 21.7113°, 22.2702°, 22.7747°, 23.2869°,
23.5219°, 29.1183° for 1:25 ratio to 15.6153°, 17.5764°, 20.3910°,
20.6406°, 21.5972°, 22.1982°, 22.4728°, 23.2686°, 28.9988°,
29.5438° for 2:25 ratio, 15.4258°, 17.5811°, 21.5946°, 22.1286°,
22.6179°, 23.2695°, 29.0084° for 3:25 ratio, and 17.5430°,
17.8048°, 20.5391°, 20.6860°, 21.8042°, 22.2481°, 22.7660°,
23.5663°, 29.1780° for 4:25 ratio. Miller indices (h, k, l) values
for 1:25 ratio were 100, 210 and 220; whereas 100, 200 and
220 for 2:25 ratio; 100, 210 and 220 for 3:25 ratio; and 100,
210 and 220 for 4:25 ratio. Different peaks confirmed that
vincristine loaded nanoparticles were crystalline in nature and
Miller Indices values further confirmed presence of nanoparticles
in face centered cubic symmetry in all ratios. Such type of
shifting in peaks has not been reported in literature and might
be due to loading of vincristine in chitosan nanoparticles. There
Fig. 6. Vincristine loaded folic acid–chitosan conjugated nanoparticles at a ratio of 3:25. (a) Average particle size and polydispersity index (b) zeta potential.
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occurred no change in the symmetry of nanoparticles with
increase in concentration of vincristine in folic acid–chitosan
conjugated nanoparticles.
3.5.4. In vitro release study
As shown in Fig. 10, 1:25 formulation showed 25% of cumu-
lative release of vincristine within 2 h and 50% in 4 h and there
was no further release of the drug with the passage of time. In
contrast formulation of 2:25 showed 2.3% release of vincristine
within 2 h and subsequently 3.85, 5.38, and 6.15% release
within 4, 6 and 8 h, respectively. Similarly, a formulation of
3:25 showed 3% release of vincristine within 2 h and for 4, 6,
and 8 h the release was 10, 25, and 35%, respectively. Formu-
lation 4:25 showed 3.07% release of vincristine within 2 h from
folic acid–chitosan conjugated nanoparticles. It is therefore
clear that 1:25 ratio was the best formulation that could release
50% of the loaded drug from folic acid–chitosan conjugated
nanoparticles under in vitro conditions.
3.5.5. Scanning electron microscopy (SEM)
SEM images of the blank and vincristine loaded folic
acid–chitosan conjugated nanoparticles are depicted in Fig. 11.
Different sized nanoparticles had spherical structure and rough
surface. Earlier, spherical chitosan and gemcitabine loaded
chitosan–pluronic® F nanoparticles have been reported [30].
Spherical shaped 5-fluorouracil loaded chitosan nanoparticles
in different ratios were also examined [24]. On the contrary,
well-formed spherical shaped, lomustine loaded chitosan-sodium
tripolyphosphate and chitosan-sodium hexametaphosphate
nanoparticles with smooth surface have also been observed
[31].
3.5.6. Transmission electron microscopy (TEM)
TEM images of blank and the vincristine loaded nanoparticles
are presented in Fig. 12. Blank nanoparticles were spherical in
structure having a size of 200 nm without any contrast inside.
Folic acid–chitosan conjugated nanoparticles in 1:25, 2:25,
3:25 and 4:25 ratios were spherical in structure with size ranging
from 4.24 to 300 nm. These nanoparticles had granule like
structures inside due to loading of vincristine in chitosan
nanoparticles which confirmed loading of vincristine in folic
acid–chitosan conjugated nanoparticles. This difference in average
particle size measured with zeta sizer as compared to TEM
Fig. 7. Vincristine loaded folic acid–chitosan conjugated nanoparticles at a ratio of 4:25. (a) Average particle size and polydispersity index (b) zeta potential.
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Fig. 8. FTIR spectra showing different functional groups: (a) blank nanoparticles, (b) vincristine and at different ratios (c) 1:25, (d) 2:25, (e) 3:25, (f) 4:25.
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Fig. 8 (continued)
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might be due to difference in sample preparation in both
techniques. Earlier we [32] have used a different approach to
synthesize spherical shaped silver nanoparticles ranging from
4.98 to 29 nm for enhanced antibacterial activity of streptomycin
against some human pathogens. Spherical shaped, gefitinib and
chloroquine loaded chitosan nanoparticles with size of
80.8 ± 9.7 nm to overcome the drug resistance have been
scrutinized by Zhao et al. [33]. Mitoxantrone loaded folic
acid–chitosan conjugated nanoparticles in size range of
39 nm–53 nm have been observed. Spherical shaped paclitaxel
loaded hydrophobically modified carboxymethyl chitosan
nanoparticles for targeted delivery against mouse fibroblast
NIH 3T3 and human cervical carcinoma (Hela) were synthesized
earlier by Sahu et al. [34].
4. Conclusion
Folic acid–chitosan conjugated nanoparticles were synthesized
by keeping folic acid–chitosan conjugate (25 ml) and sodium
tripolyphosphate (5 ml) constant. Vincristine in different
Fig. 8 (continued)
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Fig. 9. XRD diffractogram with crystalline peaks of vincristine loaded folic acid–chitosan conjugated nanoparticles at different ratios: (a) 1:25, (b) 2:25, (c) 3:25,
(d) 4:25.
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Fig. 10. In vitro release study of vincristine loaded FA–CS nanoparticles at pH 6.7.
Fig. 11. SEM images of nanoparticles showing spherical shaped (a) blank and at different ratios (b) 1:25, (c) 2:25, (d) 3:25, (e) 4:25.
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formulations [100 μl (1:25), 200 μl (2:25), 300 μl (3:25), 400 μl
(4:25)] was loaded in folic acid–chitosan conjugated nanoparticles.
Maximum encapsulation efficiency (%) and actual loading
capacity (%) were 81.25 and 10.31, respectively and were
observed for 4:25 formulation. Encapsulation of vincristine
was confirmed with Fourier Transform Infrared Spectroscopy
(FTIR) and Transmission Electron Microscopy (TEM). Scanning
Electron Microscopy (SEM) revealed spherical structure and
rough surface of nanoparticles. High temperature stability analysis
showed the stability of vincristine loaded nanoparticles and
were found to be highly stable at pH 7.2 and 7.6. Positive zeta
potential also favors delivery of loaded vincristine in chitosan
nanoparticles to cancer cells. But some modifications like pH
and filtration of folic acid–chitosan conjugates in acetic acid
are recommended to obtain nanoparticles with smaller and
uniform size with good polydispersity index. These results
suggested that all formulations were important but 4:25 ratio
was the best because of high encapsulation efficiency and loading
capacity of vincristine in folic acid–chitosan conjugated
nanoparticles and they can be used for targeted delivery to
cancer cells with some modifications.
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